NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30

Nurix Therapeutics, Inc.

Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026

$24.93+0.51 (+2.09%)

Close on Oct 19, 2026

Community

Notes and questions about Nurix Therapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Nurix Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NRIX.

Revenue growth738.8% · median 17.5%

Operating margin41.3% · median -71.4%

Net margin42.0% · median -51.7%

Advertisement
300 × 250